Protagonist Therapeutics PTGX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's financing cash flow?
- Protagonist Therapeutics (PTGX) reported financing cash flow of $23.37M in Q1 2026.
- How has Protagonist Therapeutics's financing cash flow changed year-over-year?
- Protagonist Therapeutics's financing cash flow increased by 104.3% year-over-year, from $11.44M to $23.37M.
- What is the long-term trend for Protagonist Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's financing cash flow has grown at a -35.2% compound annual growth rate (CAGR), from $129.92M to $22.86M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.